Stock SPAG SPAGO NANOMEDICAL AB
Add to a list
To use this feature you must be a member
Log inSign up

All News Spago Nanomedical AB

Equities

SPAG

SE0004899474

Market Closed - Nasdaq Stockholm
Other stock markets
 09:52:18 2024-05-02 am EDT 		5-day change 1st Jan Change
0.358 SEK -3.76% Intraday chart for Spago Nanomedical AB +23.45% +9.48%
Apr. 24 Spago Nanomedical AB Reports Favorable Data in Breast Cancer Model with Tumorad CI
Apr. 16 Spago Nanomedical AB Announces Appointment of Birgitta Rembratt Svensson as Head of CMC & Supply, Effective June 1, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Spago Nanomedical : Interim ReportQ12024
PU
Spago Nanomedical interim report January-March 2024
AQ
Spago Nanomedical AB Reports Favorable Data in Breast Cancer Model with Tumorad
CI
Spago Nanomedical reports favorable data in breast cancer model with Tumorad
AQ
Spago Nanomedical strengthens management with Head of CMC and Supply
AQ
Spago Nanomedical strengthens management with Head of CMC & Supply
AQ
Spago Nanomedical AB Announces Appointment of Birgitta Rembratt Svensson as Head of CMC & Supply, Effective June 1, 2024
CI
BioStock: Spago Nanomedical's CEO: "huge commercial opportunities are unfolding"
AQ
BioStock: 2023 springboard for Spago's radionuclide cancer therapy
AQ
Spago Nanomedical Q4 Update
AQ
Spago Nanomedical year-end report January-December, 2023
AQ
Spago Nanomedical AB Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Spago Nanomedical AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
The rights issue and the directed share issue to certain guarantors in Spago Nanomedical fully registered
AQ
Spago Nanomedical presents at Redeye's Fight Cancer event on January 24
AQ
Spago Nanomedical presents at Redeye’s Fight Cancer event on January 24
AQ
BioStock: Spago's phase I/IIa cancer trial progressing steadily
AQ
Spago Nanomedical Proceeds to the Next Dose Level in the Phase I/IIa Study Tumorad-01
CI
Spago Nanomedical proceeds to the next dose level in the phase I/IIa study Tumorad-01
AQ
Spago Nanomedical - Update after funding and initiation of Tumorad
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SPAG Stock
  4. News Spago Nanomedical AB